What If Therapy Leaves a Biological Trace?

Ketamine-assisted psychotherapy research provides a window into gene expression.

• Ketamine-Assisted Psychotherapy acts like a biological reset button to stabilize the body’s stress systems.
• Therapy might actually rewrite how your genes react to pressure by smoothing out volatile molecular patterns.
• Lasting healing comes from consolidation where the brain weaves new insights into its actual physical makeup.
• We are discovering that mental breakthroughs leave a permanent footprint on the very structure of DNA.

For decades, mental health treatment has been evaluated primarily through one lens: do patients feel better? While this remains essential, it leaves open a deeper question — what actually changes when healing occurs?

For individuals living with major depressive disorder (MDD), this question is especially pressing. Many treatments offer partial or temporary relief, and even when symptoms improve, it is often unclear whether those changes reflect a deeper shift or a more fragile state.

A growing area of research is beginning to explore this question from a different angle, beyond just psychological outcomes but biological ones as well.

What is Ketamine-Assisted Psychotherapy?

Ketamine-assisted psychotherapy (KAP) has drawn attention in recent years for its rapid antidepressant effects, particularly in individuals who have not responded to conventional treatments. But beyond symptom reduction, clinicians often report something more difficult to quantify — patients describe a sense of “reset,” loosening of rigid patterns, or a newfound ability to process experiences that previously felt overwhelming.

Until recently, these observations have been largely subjective. That may be changing.

In a new longitudinal study examining DNA methylation patterns before and after KAP, our lab tracked how gene regulation shifts across time. Importantly, the design included more than a simple before-and-after comparison. By collecting multiple baseline measurements prior to treatment, we were able to distinguish natural fluctuations from changes that emerge following the intervention.

What emerged was not a dramatic biological switch, but something far more interesting.

Rather than a single pathway turning “on” or “off,” the data suggest coordinated, small-scale changes across systems involved in stress response, cellular signaling, and gene expression. These patterns appear to move toward greater stability — less volatility, more consistency. In practical terms, the biology begins to resemble a system that is no longer operating under constant strain.

How does change occur in the brain? How do we change our minds?

What if ketamine-assisted therapy could rewrite your genes? (Image Source: ChatGPT)

One way to understand this is through the concept of consolidation.

In psychotherapy, consolidation refers to the process by which new insights and emotional experiences become integrated over time. It is not the moment of realization itself that produces lasting change, but what happens afterward — how that experience is processed, revisited, and woven into a person’s sense of self.

The emerging biological findings, which will be presented at three international conferences this summer, suggest that something analogous may be occurring at the molecular level. Instead of a transient effect, there may be a gradual recalibration that supports the persistence of therapeutic gains.

This perspective aligns with a common clinical observation: the most meaningful changes in KAP often unfold not during the session itself, but in the days and weeks that follow. Patients describe shifts in how they relate to memories, to stress, and to themselves — changes that feel less like a temporary lift and more like a reorganization.

Of course, this research is still in early stages. These findings do not establish causality, nor do they imply that any single approach is universally effective. But they do point toward a more integrated understanding of mental health in which psychological and biological processes are irrevocably intertwined.

For those with clinical depression, this evolving framework may offer something important: a way of thinking about treatment not just as symptom management, but as a process that can potentially reshape underlying patterns over time.

Our research in this area is ongoing to better understand how these biological changes relate to clinical outcomes in real-world settings. We are continuing to examine patients receiving KAP as part of structured therapeutic care.

It’s More Than the Substance

At the same time, growing public and clinical interest in KAP has created a parallel need within the professional community. Many mental health providers are encountering questions about ketamine in their practice, often before they have had access to formal training in how to work with it safely and effectively. Unlike more familiar interventions, KAP requires not only knowledge of dosing and protocol, but also skill in supporting altered states and facilitating integration afterwards.

In response, several training initiatives have begun to emphasize experiential learning alongside clinical guidance, reflecting a broader shift in how emerging treatments are introduced into practice. These efforts aim to ensure that innovation is matched by competence, and that patient care remains grounded in ethical, evidence-informed frameworks.

As the field continues to develop, one thing is becoming increasingly clear: the future of mental health care may not lie in choosing between biological and psychological models, but in understanding how they come together. Healing, it seems, may leave traces in both.

More Information

To learn more about this KAP research study taking place at the University of Ottawa, visit the Laboratory for Culture and Mental Health Disparities: KAP for Major Depressive Disorder Study.

Read about the importance of training and opportunities for clinicians to learn how to deliver ketamine-assisted therapy.

References

Nepton, A., Farahani, H., Kaminsky, Z., Nucci, M., Williams, M., Mikhail, M., Perez Rosal, S & Faber, S. (2026, June 4–6). Longitudinal DNA methylation patterns associated with ketamine-assisted psychotherapy in major depressive disorder [Oral Presentation]. To be presented at the Interdisciplinary Conference on Psychedelic Research (ICPR 2026), The Netherlands.

Nepton, A., Faber, S., Perez-Rosal, S., & Williams, M. T. (2026, June 27–30). A consolidation gate linking ketamine signaling to durable epigenetic remodeling in depression [Poster]. To be presented at the 12th Congress of the European Academy of Neurology (EAN) Conference, Geneva, Switzerland.

Nepton, A., Farahani, H., Faber, S. C., & Williams, M. T. (2026, June 4–6). Genome-wide DNA methylation and psychological changes following ketamine-assisted psychotherapy for major depressive disorder. [Oral presentation] (Clinical Neuropsychology). To be presented at the Canadian Psychological Association (CPA) Annual National Convention, Montreal, Quebec, Canada